A Randomized, Single-dose, Crossover, Two-period, Pilot Comparative Bioavailability Study of Alendronate 70 mg effervescent vs. Fosamax 70 mg tablets in Healthy Male and Female Subjects.
Phase 1
- Conditions
- not applicable (submitted trial is a comparative bioavailability study)MedDRA version: 20.0Level: PTClassification code: 10031282Term: Osteoporosis Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
- Registration Number
- CTIS2024-513615-26-00
- Lead Sponsor
- Oractive Swiss AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method